KOR agonist functional selectivity in peripheral sensory neurons
KOR 激动剂在外周感觉神经元中的功能选择性
基本信息
- 批准号:9301785
- 负责人:
- 金额:$ 4.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-15 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adenylate CyclaseAdverse drug effectAdverse effectsAfferent NeuronsAffinityAgonistAnalgesicsBehavioralBehavioral AssayBehavioral ModelBindingBiological ModelsCell Culture TechniquesCellsCharacteristicsCoupledDataDevelopmentDrug IndustryEvaluationFigs - dietaryHealthLeadLigandsMAPK8 geneMediatingMitogen-Activated Protein KinasesModelingModificationMolecular ConformationN-terminalNeuronsOpioid ReceptorPainPain managementPathway interactionsPatternPeripheralPharmaceutical PreparationsPhenotypePhosphotransferasesPhysiologicalPrimary Cell CulturesProcessRattusRegulationSignal PathwaySignal TransductionSpecificityStructureStructure-Activity RelationshipSystemTestingTextTherapeuticTherapeutic AgentsTreatment EfficacyWorkanalogbasebehavior testdrug developmentdrug discoveryefficacy evaluationimprovedin vivonovel therapeuticsperipheral painreceptorresponsesalvinorin Ascaffoldtransmission process
项目摘要
DESCRIPTION (provided by applicant): Functional selectivity, also known as "biased agonism", is a term used to describe the ability of drugs, acting at the same receptor subtype, to differentially regulate the activity of each of the multiple signaling cascades coupled to the receptor. The underlying mechanism for functional selectivity is based upon the formation of ligand-specific receptor conformations that are dependent upon ligand structure and that have differential ability to regulate various cellular signal transduction molecules. There is now tremendous excitement over the potential of functional selectivity to revitalize the drug discovery/development process. Ligands with high efficacy for specific signaling pathways (or specific patterns of signaling) that mediate beneficial effects, and with minimal activity at pathways that lead to adverse effects, are expected to have improved therapeutic efficacy. However, the pharmaceutical industry has been slow to incorporate ligand functional selectivity into the drug discovery process in large part because there have been few examples of ligand functional selectivity in physiologically relevant cell systems or in vivo. If successful, the work
proposed here will help to establish the relevance of signaling specificity in a therapeutically relevant behavioral model of antinociception. We propose to demonstrate that ligand efficacy for specific signaling pathways associated with antinociception can be finely tuned by structural modifications to a ligand. In this application, we propose to use U50,488 and Salvinorin-A (Sal-A) as scaffolds to develop functionally selective analogs that maintain high efficacy for signaling
pathways that lead to antinociception and minimize activity toward anti-antinociceptive signaling pathways. Our specific aims are to 1) modify the structure of the KOR agonist, Sal-A, and 2) modify the structure of the KOR agonist, U50,488, to minimize efficacy for MAPK (ERK and JNK) signaling while maintaining (or enhancing) efficacy for activation of Gai signaling. Analogs of Sal-A and U50,488 will be synthesized in an iterative cycle of synthesis/evaluation/redesign until compounds with the proposed pharmacological characteristics of high KOR affinity and efficacy for antinociception (Gai signaling) and low efficacy for MAPK signaling (anti-antinociceptive) are obtained. Initial efficacy evaluation will be done utilizing an ex vivo model (primary sensory neuron cultures) that provides high predictability of antinociceptive efficacy in vivo. Compounds that reach the efficacy criteria ex vivo will be further tested for antinociceptive
efficacy in a complementary in vivo behavioral model of pain. This work will be the first to examine structure-activity relationships of functionally selective ligands using a physiologically-
and therapeutically-relevant model system to guide compound development. If successful, this work will not only establish the importance of functional selectivity in physiological systems and thereby herald fundamental changes in drug development strategies, but also may lead to new drugs with improved therapeutic profiles for the treatment of pain.
描述(由申请人提供):功能选择性,也称为“偏向激动作用”,是用于描述药物作用于相同受体亚型差异调节与受体偶联的多个信号级联中的每一个的活性的能力的术语。功能选择性的潜在机制是基于配体特异性受体构象的形成,所述配体特异性受体构象依赖于配体结构并且具有调节各种细胞信号转导分子的不同能力。现在,人们对功能选择性振兴药物发现/开发过程的潜力感到非常兴奋。预期对介导有益作用的特定信号传导途径(或特定信号传导模式)具有高功效且对导致不良作用的途径具有最小活性的配体具有改善的治疗功效。然而,制药工业在将配体功能选择性纳入药物发现过程中方面进展缓慢,这在很大程度上是因为在生理学相关的细胞系统或体内很少有配体功能选择性的实例。如果成功,工作
本文提出的方法将有助于建立抗伤害感受的治疗相关行为模型中信号特异性的相关性。我们建议证明,与抗伤害感受相关的特定信号通路的配体功效可以通过对配体的结构修饰进行微调。在本申请中,我们提出使用U 50,488和Salvinorin-A(Sal-A)作为支架来开发功能选择性类似物,其维持对信号传导的高功效
导致抗伤害感受的通路,并使抗伤害感受信号通路的活性最小化。我们的具体目标是1)修饰KOR激动剂Sal-A的结构,和2)修饰KOR激动剂U 50,488的结构,以使MAPK(ERK和JNK)信号传导的功效最小化,同时维持(或增强)激活Gai信号传导的功效。Sal-A和U 50,488的类似物将在合成/评估/重新设计的迭代循环中合成,直到获得具有高KOR亲和力和抗伤害感受功效(Gai信号传导)以及低MAPK信号传导功效(抗-抗伤害感受)的所提出的药理学特征的化合物。将利用离体模型(初级感觉神经元培养物)进行初始疗效评价,该模型可提供体内抗伤害感受疗效的高度可预测性。将进一步测试离体达到功效标准的化合物的抗伤害感受性。
在疼痛的补充体内行为模型中的功效。这项工作将是第一个使用生理学方法研究功能选择性配体的结构-活性关系的工作。
和治疗相关的模型系统来指导化合物的开发。如果成功,这项工作不仅将确立生理系统中功能选择性的重要性,从而预示着药物开发策略的根本性变化,而且还可能导致具有改善的疼痛治疗特征的新药。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM P CLARKE其他文献
WILLIAM P CLARKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM P CLARKE', 18)}}的其他基金
Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia
DOR-KOR 异聚体介导的外周镇痛变构分子的鉴定
- 批准号:
10608439 - 财政年份:2023
- 资助金额:
$ 4.06万 - 项目类别:
Development of a phenotypic screening assay for novel compounds that inhibit peripheral pain-sensing neurons
开发抑制外周痛觉神经元的新型化合物的表型筛选试验
- 批准号:
10650640 - 财政年份:2023
- 资助金额:
$ 4.06万 - 项目类别:
Pharmacological and behavioral effects of MCAM: a long-acting, μ opioid receptor antagonist for treatment of opioid overdose and opioid abuse disorder
MCAM 的药理和行为影响:一种长效、μ阿片受体拮抗剂,用于治疗阿片类药物过量和阿片类药物滥用障碍
- 批准号:
10091419 - 财政年份:2019
- 资助金额:
$ 4.06万 - 项目类别:
Pharmacological and behavioral effects of MCAM: a long-acting, μ opioid receptor antagonist for treatment of opioid overdose and opioid abuse disorder
MCAM 的药理和行为影响:一种长效、μ阿片受体拮抗剂,用于治疗阿片类药物过量和阿片类药物滥用障碍
- 批准号:
9923616 - 财政年份:2019
- 资助金额:
$ 4.06万 - 项目类别:
Regulation of Kappa opioid receptor-mediated signaling and peripheral analgesia
Kappa 阿片受体介导的信号传导和外周镇痛的调节
- 批准号:
8972021 - 财政年份:2014
- 资助金额:
$ 4.06万 - 项目类别:
Regulation of Kappa opioid receptor-mediated signaling and peripheral analgesia
Kappa 阿片受体介导的信号传导和外周镇痛的调节
- 批准号:
8794814 - 财政年份:2014
- 资助金额:
$ 4.06万 - 项目类别:
Regulation of Kappa opioid receptor-mediated signaling and peripheral analgesia
Kappa 阿片受体介导的信号传导和外周镇痛的调节
- 批准号:
8632174 - 财政年份:2014
- 资助金额:
$ 4.06万 - 项目类别:
Regulation of DOR-KOR heteromer formation in pain-sensing neurons
痛觉神经元中 DOR-KOR 异聚体形成的调节
- 批准号:
8824055 - 财政年份:2014
- 资助金额:
$ 4.06万 - 项目类别:
Regulation of opioid receptor function in trigeminal ganglion
三叉神经节阿片受体功能的调节
- 批准号:
8094524 - 财政年份:2009
- 资助金额:
$ 4.06万 - 项目类别: